WEX Launches HRA for GLP-1 Drugs as 34 Million Americans Qualify
WEX has launched a specialized defined-contribution HRA for GLP-1 medications, enabling employers to carve out coverage with customizable funding and reimbursement rules to shield core medical plans from premium inflation. Nearly 34 million Americans qualify for these weight-management drugs as employer coverage rose to 19% among large organizations in 2025.
1. Launch of Specialized GLP-1 HRA
WEX has introduced a defined-contribution Health Reimbursement Arrangement focused on GLP-1 medications, allowing employers to carve out coverage from core medical plans and manage unpredictable utilization and premium inflation.
2. Key Features and Benefits
The HRA offers customizable funding parameters, tailored reimbursement rules and proprietary payment rails, enabling employees to access GLP-1 drugs through pharmacies, manufacturer-direct programs or alternative channels under clear employer-controlled budgets.
3. Market Context and Demand
GLP-1 medications now qualify nearly 34 million Americans for weight-management treatment, and 19% of organizations with 200+ employees included these drugs in 2025, creating higher premiums and plan exposure for employers.
4. Availability and Implementation
The GLP-1 HRA is available immediately to employers, brokers and consultants through WEX’s benefits network, integrating with existing workflows to reduce manual administration and maintain compliance.